Millennium Management LLC Cuts Stock Position in Humacyte, Inc. (NASDAQ:HUMA)

Millennium Management LLC lowered its stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 27.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 918,854 shares of the company's stock after selling 348,653 shares during the quarter. Millennium Management LLC owned 0.73% of Humacyte worth $4,640,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Vontobel Holding Ltd. acquired a new stake in Humacyte in the 4th quarter valued at $50,000. Petros Family Wealth LLC acquired a new stake in Humacyte in the 4th quarter valued at $50,000. Syon Capital LLC acquired a new stake in Humacyte in the 4th quarter valued at $54,000. Ameriprise Financial Inc. acquired a new stake in Humacyte in the 4th quarter valued at $58,000. Finally, Hsbc Holdings PLC acquired a new stake in Humacyte in the 4th quarter valued at $62,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte Stock Performance

Shares of HUMA stock traded down $0.05 on Monday, hitting $2.62. 4,519,470 shares of the stock traded hands, compared to its average volume of 3,782,465. The firm's 50-day moving average price is $1.72 and its two-hundred day moving average price is $3.26. The stock has a market capitalization of $406.41 million, a PE ratio of -1.96 and a beta of 1.64. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. On average, equities research analysts anticipate that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Analyst Ratings Changes

HUMA has been the topic of a number of research analyst reports. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, May 13th. Benchmark decreased their price objective on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, HC Wainwright initiated coverage on Humacyte in a report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $11.71.

Insider Activity at Humacyte

In other Humacyte news, Director Kathleen Sebelius purchased 50,000 shares of the business's stock in a transaction on Tuesday, April 8th. The shares were bought at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the purchase, the director now directly owns 91,207 shares of the company's stock, valued at approximately $120,393.24. This trade represents a 121.34% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dale A. Sander purchased 20,000 shares of the business's stock in a transaction on Thursday, April 10th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at approximately $62,118. This trade represents a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 83,993 shares of company stock worth $118,224. Company insiders own 5.10% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.